The US market for contrast agents and radiopharmaceuticals will be limited by reimbursement restrictions and lower dosing; nonetheless, growth in the large radiopharmaceutical market and favorable demographics will result in a modest expansion of the market through 2023.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals across a 10-year period.
Geographies Covered: US
Procedures and Products Covered: DRG's analysis uses the following breakdown of procedures and products in the market:
CT and X-Ray Contrast Agents*
MRI Contrast Agents**
Ultrasound Contrast Agents***
Notes: (1) *Only injectable iodinated contrast agents are included; barium-based agents used as bowel markers for these modalities are excluded. (2) **Only gadolinium-based MRI contrast agents are included. (3) ***Installed base values are not included. The market model only includes ultrasound contrast agents used for echocardiography and excludes all other ultrasound procedures.
Market Forecast Features: Based on primary research with industry professionals, DRG uses its proprietary forecasting model to provide an in-depth examination of current and future trends in procedure volumes, ASPs, market values, and the installed base over a 10-year period (2013–2023).
Competitive Analysis: DRG provides a detailed analysis of the competitive landscape and market shares for leading competitors.